Results 171 to 180 of about 1,686,414 (204)

The tangled history of mRNA vaccines

Nature, 2021
Hundreds of scientists had worked on mRNA vaccines for decades before the coronavirus pandemic brought a breakthrough. Hundreds of scientists had worked on mRNA vaccines for decades before the coronavirus pandemic brought a breakthrough.
openaire   +2 more sources

The safety and immunogenicity of two Zika virus mRNA vaccine candidates in healthy flavivirus baseline seropositive and seronegative adults: the results of two randomised, placebo-controlled, dose-ranging, phase 1 clinical trials.

Lancet. Infectious Diseases (Print), 2023
BACKGROUND Developing a safe and immunogenic vaccine against Zika virus remains an unmet medical need. We did two phase 1 studies that evaluated the safety and immunogenicity of two mRNA-based Zika virus vaccines (mRNA-1325 and mRNA-1893) in adults ...
B. Essink, L. Chu, W. Seger, E. Barranco, N. Le Cam, H. Bennett, Veronica Faughnan, R. Pajon, Y. Paila, Brooke Bollman, Steven Wang, J. Dooley, S. Kalidindi, B. Leav   +13 more
semanticscholar   +1 more source

A multivalent nucleoside-modified mRNA vaccine against all known influenza virus subtypes

Science, 2022
Seasonal influenza vaccines offer little protection against pandemic influenza virus strains. It is difficult to create effective prepandemic vaccines because it is uncertain which influenza virus subtype will cause the next pandemic.
C. P. Arevalo, M. Bolton, Valerie Le Sage, Naiqing Ye, Colleen Furey, Hiromi Muramatsu, M. Alameh, N. Pardi, E. Drapeau, Kaela Parkhouse, Tyler A. Garretson, J. S. Morris, L. Moncla, Ying K. Tam, Steven H. Y. Fan, S. Lakdawala, D. Weissman, S. Hensley   +17 more
semanticscholar   +1 more source

Nanotechnology-based mRNA vaccines

Nature Reviews Methods Primers, 2023
mRNA vaccines have emerged as a revolutionary tool to generate rapid and precise immune responses against infectious diseases and cancers. Compared with conventional vaccines such as inactivated viruses, viral vectors, protein subunits or DNA-based vaccines, mRNA vaccines stand out owing to multiple advantages, including simplicity of design, fast ...
Shuying Chen, Xiangang Huang, Yonger Xue, Ester Álvarez-Benedicto, Yesi Shi, Wei Chen, Seyoung Koo, Daniel J. Siegwart, Yizhou Dong, Wei Tao   +9 more
openaire   +2 more sources

Spleen-Targeted mRNA Vaccine Doped with Manganese Adjuvant for Robust Anticancer Immunity In Vivo.

ACS Nano
The successful application of mRNA vaccines in preventing and treating infectious diseases highlights their potential as therapeutic vaccines for cancer treatment.
Zijin Luo, Yi Lin, Yanan Meng, Mengyao Li, Hongyu Ren, Haoping Shi, Q. Cheng, Tuo Wei   +7 more
semanticscholar   +1 more source

Recent innovations in mRNA vaccines

Current Opinion in Immunology, 2016
Nucleic acid-based vaccines are being developed as a means to combine the positive attributes of both live-attenuated and subunit vaccines. Viral vectors and plasmid DNA vaccines have been extensively evaluated in human clinical trials and have been shown to be safe and immunogenic, although none have yet been licensed for human use.
Jeffrey B Ulmer, Andrew J Geall
openaire   +2 more sources

mRNA vaccine sequence and structure design and optimization: Advances and challenges

Journal of Biological Chemistry
Messenger RNA (mRNA) vaccines have emerged as a powerful tool against communicable diseases and cancers, as demonstrated by their huge success during the coronavirus disease 2019 (COVID-19) pandemic.
Lei Jin, Yuanzhe Zhou, Sicheng Zhang, Shi-Jie Chen   +3 more
semanticscholar   +1 more source

A spike-based mRNA vaccine that induces durable and broad protection against porcine deltacoronavirus in piglets

Journal of Virology
Coronaviruses (CoVs) are important pathogens for humans and other vertebrates, causing severe respiratory and intestinal infections that have become a threat to public health because of the potential for interspecies transmission between animals and ...
Jizong Li, Li Xiao, Zhuoqi Chen, Liyuan Fan, Wei Wang, Rong-li Guo, Zhaoming He, Hongpeng Hu, Jianhao Jiang, Lixiang Zhao, Tianyi Zhong, B. Fan, Xing Zhu, Bin Li   +13 more
semanticscholar   +1 more source

A phase 3 randomized safety and immunogenicity trial of mRNA-1010 seasonal influenza vaccine in adults.

Vaccine
BACKGROUND Messenger RNA (mRNA)-based influenza vaccines have the potential to improve upon limitations of current vaccine approaches to seasonal influenza.
Mieke Soens, J. Ananworanich, Bryony Hicks, K. Lucas, J. Cardona, Lawrence D Sher, Greg Livermore, Kristi Schaefers, Carole Henry, Angela Choi, A. Avanesov, Ren Chen, Evelyn Du, Alicia Pucci, R. Das, Jacqueline Miller, R. Nachbagauer   +16 more
semanticscholar   +1 more source

mRNA vaccines

Nature Biotechnology
Phei Er Saw, Erwei Song
  +6 more sources